Skip to main content
Premium Trial:

Request an Annual Quote

Incyte s Revenues Take a Dive, Losses Narrow in Q1

NEW YORK, May 4 (GenomeWeb News) - Incyte's revenues were almost cut in half, while its losses narrowed during Q1 of 2004, the company reported today.


Revenues for the quarter plummeted to $6.6 million, from $12.5 million during the same period last year. Incyte attributed this decrease to the discontinuation of its genomic data products.


R&D costs decreased to $26.2 million, down from $30.2 million during the first quarter of 2003.


Incyte's net loss decreased to $37.7 million, or $.52 per share, from $55.8 million, or $.81 per share, during the year-ago period.


As of March 31, Incyte had $500.7 million in cash, cash equivalents and marketable securities, compared to $293.8 million at the end of 2003. This increase results from the company's sale of convertible subordinated notes, which generated net proceeds of $242 million.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.